GlobeNewswire

2024-11-13 23:57

Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer

ST. LOUIS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that its ECLIPSE trial met its primary endpoint. ECLIPSE is a pivotal Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T (INN: lutetium (177Lu) zadavotide guraxetan) versus hormone therapy in patients with metastatic castration-resistant prostate cancer.

The ECLIPSE trial demonstrated a statistically significant and clinically meaningful improvement in the median radiographic progression-free survival (rPFS) of patients with prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with up to 6 doses of 200 mCi (7.4 GBq) of 177Lu-PSMA-I&T in patients previously treated with an androgen receptor pathway inhibitor (ARPI) compared to a change in ARPI.

Sakir Mutevelic, MD, Curium’s Chief Medical Officer said: “This is a significant accomplishment for Curium, demonstrating in the pivotal confirmatory ECLIPSE trial a statistically significant and clinically meaningful benefit of PSMA-targeted radioligand therapy with 177Lu-PSMA-I&T for patients with mCRPC. ECLIPSE is the first Phase 3 trial investigating a 200 mCi (7.4 GBq) dose of 177Lu-PSMA-I&T administered every six weeks for up to six doses, demonstrating clinical benefit, in mCRPC patients before receiving taxane-based chemotherapy. Curium will continue to work with the FDA as the clinical trial data matures, on a regulatory submission plan for this potentially important product for patients, their caregivers, and the healthcare providers treating prostate cancer.”

Michael Patterson, CEO, Curium North America added: “The ECLIPSE achievement of its primary endpoint represents an important clinical milestone in the development of our prostate theranostic program. This underscores Curium’s continued commitment and focus on nuclear medicine diagnostics and therapeutics. Further, the announcement of the opening of Curium’s Netherlands facility for the production of 177Lutetium in September 2024, bolsters Curium’s supply chain and ensures manufacturing reliability.   Curium will continue to work to fulfill its mission of redefining the experience of cancer through our trusted legacy in nuclear medicine by ensuring unrestricted access to this important product, if approved.”

About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com.

For more information:
Ross Bethell, VP, Head of Global Communications
communications@curiumpharma.com


Primary Logo

source: Curium

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞! ► 即睇詳情

人氣文章
最近7天
1
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
2
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
3
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
4
港股 | 蕭猷華:恒指維持19700點至21000點上落
5
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
6
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
7
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
8
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
9
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
10
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
1
高息定存 | 一周高息合集,信銀國際3個月有3.88厘
2
高息定存 | 工銀亞洲新推38日4.08厘,集友3個月加至3.7厘
3
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
4
高息定存 | 一周高息合集,大新3個月最高4.1厘,華僑及信銀國際見4厘
5
【FOCUS】豪賭折射威權脆弱,尹錫悅去留牽動地緣
6
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
7
南韓戒嚴 | 韓國防部長金龍顯辭職
8
高息定存 | 華僑推3個月快閃達4厘,信銀國際全線升3個月存息
9
港股 | 蕭猷華:恒指料反彈,短線看幾多?
10
呂志和喪禮|呂志和香港殯儀館設靈,中聯辦鄭雁雄、李家超、陳啟宗等人到場(圖集)
11
局長換人 | 國務院:免去林世雄、楊潤雄局長職務,任命陳美寶、羅淑佩接任(楊潤雄facebook回應)
12
熊貓經濟 | 2500隻大熊貓雕塑抵港,周六起星光大道等地展出
13
一周部署 | 非農數據前美股料穩,OPEC+會議全球矚目
14
傾力救市 | 華爾街大行預計中國明年降息幅度將達十年來最大
15
建銀國際料明年恒指先低後高,波動區間18000至23000點
16
高息定存 | 建行亞洲上調3個月存息至3.85厘,富邦3.8厘
17
港股 | 蕭猷華:關注中央經濟工作會議,美團股價落後
18
高息定存 | 華僑銀行208日定存年息高達3.8厘
19
基建債券 | 認購額178.5億首未足額,發言人:受減息步伐影響
20
神州經脈 | 政治局會議定調明年貨幣政策適度寬鬆,CPI遜預期
21
新股 |【FOCUS】毛戈平膺「凍資王」,驚艷之後魅力臨考
22
詹培忠父子涉隱瞞秘密「買殼」串謀欺詐罪成
23
神州經脈 | 11月進出口數據降溫,貨幣政策轉向股匯齊漲
24
神州經脈 | 回購增持貸細則調整,13美國軍工企業遭反制
25
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
26
神州經脈 | 深圳恢復赴港一簽多行,本月買斷式逆回購8000億
27
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
28
特首述職|習近平讚揚李家超務實進取,中央全力支持帶領各界改革
29
滙控 | 擬推改革削減成本,股價再創17年新高,聖誕鐘真係要買滙豐?
30
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Moon-River RELOVE 蛋白酵素去漬抑菌手洗精 (價值HK$188)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

回顧24 展望25

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老